{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"title":"Confirmed Objective response rate (ORR), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"title":"Confirmed Objective response rate (ORR), 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Confirmed Complete response (CR), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Confirmed Complete response (CR), 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"title":"Confirmed Partial response (PR), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"title":"Confirmed Partial response (PR), 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}]}],"title":"Confirmed Stable disease (SD), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}]}],"title":"Confirmed Stable disease (SD), 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"title":"Confirmed Progressive disease (PD), 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"title":"Confirmed Progressive disease (PD), 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Inevaluable, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Inevaluable, 36 months (DCO: Dec 11, 2020)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Independent Central Review (ICR) based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Confirmed ORR and BOR (confirmed by ICR) are reported.","groups":[{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG000","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG001","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Best overall response was assessed in the Exploratory Cohorts in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"From randomization to first documented objective response, up to 36 months postdose","title":"Objective Response Rate and Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)","type":"SECONDARY","unitOfMeasure":"Participants"}